Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Landos Leverages Advanced Computing For Autoimmune Disease Drug Development

Executive Summary

Emerging Company Profile: Start-up Landos is raising money through a Series B financing to fund Phase II development of its lead oral, gut-restricted compound and described its plans in a video interview at the Biotech Showcase in San Francisco in January. 

 

 

Advertisement

Related Content

Theravance Banks $100m As J&J Bets Big On IBD Drug
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends
The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies
Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel